2010
DOI: 10.1016/s1054-3589(10)58013-x
|View full text |Cite
|
Sign up to set email alerts
|

GABAB Receptors in Reward Processes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
79
0

Year Published

2012
2012
2021
2021

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 103 publications
(83 citation statements)
references
References 152 publications
4
79
0
Order By: Relevance
“…Rats receiving these microinjections were more sensitive to the rewarding effects of ethanol. Considering that the enhanced preference to drug-paired environments and rewarding effects of psycho-stimulants appear to depend on common neural substrates (Green and Grahame, 2008;McBride et al, 1999;Risinger et al, 1994;Vlachou and Markou, 2010), these findings raised the possibility that reduced expression of mGlu7 receptors in the mesolimbic system would also affect the rewarding effects of ethanol. Indeed, lower doses of alcohol established-conditioned-place preferences in rats given this treatment, suggesting that these rats were more sensitive to the rewarding effects of the drug.…”
Section: Discussionmentioning
confidence: 99%
“…Rats receiving these microinjections were more sensitive to the rewarding effects of ethanol. Considering that the enhanced preference to drug-paired environments and rewarding effects of psycho-stimulants appear to depend on common neural substrates (Green and Grahame, 2008;McBride et al, 1999;Risinger et al, 1994;Vlachou and Markou, 2010), these findings raised the possibility that reduced expression of mGlu7 receptors in the mesolimbic system would also affect the rewarding effects of ethanol. Indeed, lower doses of alcohol established-conditioned-place preferences in rats given this treatment, suggesting that these rats were more sensitive to the rewarding effects of the drug.…”
Section: Discussionmentioning
confidence: 99%
“…Such receptor heterogeneity would allow more selective manipulation of the GABA B system. GABA B receptor-positive modulators are thought to have advantages as potential medications for anxiety, depression, and drug addiction (Cryan et al, 2004;Frankowska et al, 2007;Jacobson and Cryan, 2008;Vlachou and Markou, 2010), because they may have a better side effect profile than GABA B receptor agonists, based on the notion that selective enhancement of activated receptors has effects that differ from indiscriminate activation of all receptors. Unlike baclofen, GABA B receptor-positive modulators do not seem to interfere with motor coordination (Cryan et al, 2004;Jacobson and Cryan, 2008), do not produce loss of righting (Carai et al, 2004;Malherbe et al, 2008;Koek et al, 2010) and, with the possible exception of CGP7930 (Koek et al, 2010), do not induce hypothermia (Jacobson and Cryan, 2008;Malherbe et al, 2008;Koek et al, 2010).…”
Section: Discussionmentioning
confidence: 99%
“…g-Aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system, and it binds to two major receptor types, the GABA A and GABA B receptors (Charney et al, 2006;Vlachou and Markou, 2010). GABA A receptors are ligand-gated chloride channels, and because extracellular chloride concentrations are usually greater than intracellular concentrations in neurons, activation of GABA A receptors usually causes an influx of negatively charged chloride anions that hyperpolarizes neurons and reduces neuronal excitability (Farrant and Nusser, 2005;Egawa and Fukuda, 2013).…”
Section: Gabaergic Drugsmentioning
confidence: 99%
“…A variety of other chemicals including ethanol and some volatile inhalants (e.g., toluene) also positively modulate GABA A receptor function. GABA B receptors are G i/o -protein-coupled receptors that exist as dimers of two GABA B subunits linked to inhibitory signaling pathways, including calcium channel inhibition, potassium channel activation, and inhibition of adenylate cyclase (Vlachou and Markou, 2010;Benarroch, 2012). The only clinically available GABA B ligand is the agonist baclofen, but other drugs have been developed that function as agonists, antagonists and allosteric modulators.…”
Section: Gabaergic Drugsmentioning
confidence: 99%